COVID-19 Vaccine Pfizer-BioNTech

S

Recurrence of CD30-positive lymphoproliferative disorder: case report

A 79-year-old man exhibited recurrence of CD30-positive lymphoproliferative disorder following treatment with COVID-19 Vaccine Pfizer-BioNTech.

The man presented with a 3-centimeter ulcerated tumor with surrounding erythema in the left axilla. The lesion appeared 2 days following the initial vaccination with the COVID-19 Vaccine Pfizer-BioNTech [Pfizer-BioNTech COVID-19 vaccine; *route and dosage not stated*] in the ipsilateral arm. He denied any systemic symptoms in association with receiving the vaccine. Of historical significance, he was evaluated for an ulcerated plaque on the left supraclavicular skin in April 2019. Subsequent biopsy showed a CD-30 positive lymphoproliferative disorder (CD30 LPD). Staging ruled out any systemic disease and supported a diagnosis of primary cutaneous anaplastic large-cell lymphoma. He completed 3 fractions of 600 cGy localised radiation therapy in June 2019, after which the lesion resolved. He experienced no recurrence of disease in the interim period prior to presenting for his COVID-19 Vaccine Pfizer-BioNTech. Biopsy of the current left axillary tumor showed a CD30 LPD with numerous eosinophils, similar to the pathology of 2019. A positive T-cell receptor gene rearrangement matching the 2019 clone was also identified. A diagnosis of COVID-19 Vaccine Pfizer-BioNTech-induced recurrence of CD30-positive lymphoproliferative disorder was made. Over the course of the next several weeks the tumor regressed significantly without treatment. Three weeks following his first dose, he received his second COVID-19 vaccine in the contralateral arm without developing significant side effects or new skin lesions.

Brumfiel CM, et al. Recurrence of primary cutaneous CD30-positive lymphoproliferative disorder following COVID-19 vaccination. Leukemia and Lymphoma 62: 2554-2555, No. 10, Jan 2021. Available from: URL: https://www.tandfonline.com/loi/ilal20

803618996